The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia: A Systematic Review
Abstract
OBJECTIVE: To conduct a systematic review and, where possible, quantitative meta-analysis of the existing evidence regarding the therapeutic efficacy and safety of the saw palmetto plant extract, Serenoa repens, in men with symptomatic benign prostatic hyperplasia (BPH). DATA SOURCES: Studies were identified through the search of MEDLINE (1966-1997), EMBASE, Phytodok, the Cochrane Library, bibliographies of identified trials and review articles, and contact with relevant authors and drug companies. STUDY SELECTION: Randomized trials were included if participants had symptomatic BPH, the intervention was a preparation of S repens alone or in combination with other phytotherapeutic agents, a control group received placebo or other pharmacological therapies for BPH, and the treatment duration was at least 30 days. DATA EXTRACTION: Two investigators for each article (T.J.W., A.I., G.S., and R.M.) independently extracted key data on design features, subject characteristics, therapy allocation, and outcomes of the studies. DATA SYNTHESIS: A total of 18 randomized controlled trials involving 2939 men met inclusion criteria and were analyzed. Many studies did not report results in a method that permitted meta-analysis. Treatment allocation concealment was adequate in 9 studies; 16 were double-blinded. The mean study duration was 9 weeks (range, 4-48 weeks). As compared with men receiving placebo, men treated with S repens had decreased urinary tract symptom scores (weighted mean difference [WMD], -1.41 points [scale range, 0-19] [95% confidence interval (CI), -2.52 to -0.30] [n = 1 study]), nocturia (WMD, -0.76 times per evening [95% CI, -1.22 to -0.32] [n = 10 studies]), and improvement in self-rating of urinary tract symptoms; risk ratio for improvement (1.72 [95% CI, 1.21-2.44] [n = 6 studies]), and peak urine flow (WMD, 1.93 mL/s [95% CI, 0.72-3.14] [n = 8 studies]). Compared with men receiving finasteride, men treated with S repens had similar improvements in urinary tract symptom scores (WMD, 0.37 International Prostate Symptom Score points [scale range, 0-35] [95% CI, -0.45 to 1.19] [n = 2 studies]) and peak urine flow (WMD, -0.74 mL/s [95% CI, -1.66 to 0.18] [n = 2 studies]). Adverse effects due to S repens were mild and infrequent; erectile dysfunction was more frequent with finasteride (4.9%) than with S repens (1.1%; P<.001). Withdrawal rates in men assigned to placebo, S repens, or finasteride were 7%, 9%, and 11%, respectively. CONCLUSIONS: The existing literature on S repens for treatment of BPH is limited in terms of the short duration of studies and variability in study design, use of phytotherapeutic preparations, and reports of outcomes. However, the evidence suggests that S repens improves urologic symptoms and flow measures. Compared with finasteride, S repens produces similar improvement in urinary tract symptoms and urinary flow and was associated with fewer adverse treatment events. Further research is needed using standardized preparations of S repens to determine its long-term effectiveness and ability to prevent BPH complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
The Development of Human Benign Prostatic Hyperplasia with Age
Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)49698-4 · Cited by 2,488
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Harmless Herbs? A Review of the Recent Literature
Ernst, E. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00397-5 · Cited by 634
Benign Prostatic Hyperplasia: Antecedents and Natural History
Guess, H. A. (1992) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036083 · Cited by 167
Clinical trials in psychiatry: should protocol deviation censor patient data?
Lavori, P. W. (1992) · PubMed · Cited by 158
A double‐blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia.
Champault, G., Patel, J., & Am, B. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02491.x · Cited by 129
Treatment of Benign Prostatic Hyperplasia with Phytosterols
Carbin, B.-E., LARSSON, B., & LINDAHL, O. (1990) · British Journal of Urology · doi:10.1111/j.1464-410x.1990.tb07199.x · Cited by 122
Cited by
Calixto, J. B. (2000) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2000000200004 · Cited by 1,282
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
Interactions Between Herbal Medicines and Prescribed Drugs: A Systematic Review
Izzo, A. A., & Ernst, E. (2001) · Drugs · doi:10.2165/00003495-200161150-00002 · Cited by 714
Metadata
- Authors
- Wilt, T. J., Ishani, A., Stark, G., MacDonald, R., Lau, J., & Mulrow, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1998-11-11
- Volume
- 280
- Issue
- 18
- Pages
- 1604
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2034333489
- Cited by
- 384
- References
- 14
- FWCI
- 41.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia: A Systematic Review. https://app.cochat.ai/papers/10.1001/jama.280.18.1604
- The paper
- Wilt, T. J., Ishani, A., Stark, G., MacDonald, R., Lau, J., & Mulrow, C. (1998). Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia: A Systematic Review. JAMA. https://doi.org/10.1001/jama.280.18.1604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.